[go: up one dir, main page]

MX2010002781A - Combinacion novedosa de angentes terapeuticos. - Google Patents

Combinacion novedosa de angentes terapeuticos.

Info

Publication number
MX2010002781A
MX2010002781A MX2010002781A MX2010002781A MX2010002781A MX 2010002781 A MX2010002781 A MX 2010002781A MX 2010002781 A MX2010002781 A MX 2010002781A MX 2010002781 A MX2010002781 A MX 2010002781A MX 2010002781 A MX2010002781 A MX 2010002781A
Authority
MX
Mexico
Prior art keywords
therapeutic agents
novel combination
corticosteroid
agonist
nose
Prior art date
Application number
MX2010002781A
Other languages
English (en)
Inventor
Dramane Ibrahim Laine
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of MX2010002781A publication Critical patent/MX2010002781A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se proporcionan aqu? combinaciones novedosas de un antagonista del receptor de acetilcolina muscar?nica y un agonista beta 2 y/o un corticoesteroide para su administraci?n inhalados por la nariz o por la boca, y m?todos para usarlos.
MX2010002781A 2007-09-12 2008-09-12 Combinacion novedosa de angentes terapeuticos. MX2010002781A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US97164607P 2007-09-12 2007-09-12
US9291708P 2008-08-29 2008-08-29
PCT/US2008/076122 WO2009036243A1 (en) 2007-09-12 2008-09-12 Novel combination of therapeutic agents

Publications (1)

Publication Number Publication Date
MX2010002781A true MX2010002781A (es) 2010-04-01

Family

ID=40452490

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010002781A MX2010002781A (es) 2007-09-12 2008-09-12 Combinacion novedosa de angentes terapeuticos.

Country Status (9)

Country Link
US (1) US20100329996A1 (es)
EP (1) EP2197444A1 (es)
JP (1) JP2010539182A (es)
KR (1) KR20100063116A (es)
CN (1) CN101801378A (es)
BR (1) BRPI0816255A2 (es)
MX (1) MX2010002781A (es)
RU (1) RU2010108640A (es)
WO (1) WO2009036243A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2400950T1 (sl) 2009-02-26 2019-09-30 Glaxo Group Limited Farmacevtske forlmulacije, ki obsegajo 4-((1 R)-2-((6-(2-((2,6- diklorobenzil)oksi)etoksi)heksil)amino)-1-hidroksietil)-2- (hidroksimetil)fenol
EP3061821B1 (en) 2009-07-22 2019-07-10 Puretech Health LLC Compositions for treatment of disorders ameliorated by muscarinic receptor activation
US10265311B2 (en) 2009-07-22 2019-04-23 PureTech Health LLC Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation
CA2781402C (en) 2009-11-23 2017-03-21 Palatin Technologies, Inc. Melanocortin-1 receptor-specific cyclic peptides
WO2011063367A1 (en) 2009-11-23 2011-05-26 Palatin Technologies, Inc. Melanocortin-1 receptor-specific linear peptides
GB0921075D0 (en) 2009-12-01 2010-01-13 Glaxo Group Ltd Novel combination of the therapeutic agents
WO2011081937A1 (en) * 2009-12-15 2011-07-07 Gilead Sciences, Inc. Corticosteroid-beta-agonist-muscarinic antagonist compounds for use in therapy
KR20140025308A (ko) * 2010-10-12 2014-03-04 시플라 리미티드 약학 조성물
KR20140041699A (ko) * 2011-06-08 2014-04-04 글락소 그룹 리미티드 우메클리디늄 및 코르티코스테로이드를 포함하는 조합물
EP2836204B1 (en) 2012-04-13 2020-07-08 GlaxoSmithKline Intellectual Property Development Limited Aggregate particles
KR20130140358A (ko) * 2012-06-14 2013-12-24 한미약품 주식회사 살메테롤 지나포산염, 플루티카손 프로피오네이트 및 티오트로피움 브로마이드를 포함하는 흡입 제형용 건조 분말 및 이의 제조방법
GB201222679D0 (en) * 2012-12-17 2013-01-30 Glaxo Group Ltd Pharmaceutical combination products
GB201305825D0 (en) 2013-03-28 2013-05-15 Vectura Ltd New use
CA2926432A1 (en) * 2013-10-07 2015-04-16 Teva Branded Pharmaceutical Products R&D, Inc. Dry powder inhaler
GB201408387D0 (en) * 2014-05-12 2014-06-25 Teva Pharmaceuticals Europ B V Treatment of respiratory disorders
CA2952760A1 (en) 2014-06-18 2015-12-23 Cipla Limited Pharmaceutical composition comprising a beta-2-agonist and anticholinergic agent
EP3856182B1 (en) 2018-09-28 2025-12-24 Karuna Therapeutics, Inc. Compositions and methods for treating disorders ameliorated by muscarnic receptor activation
WO2021260441A1 (en) * 2020-06-26 2021-12-30 Mylan Pharma Uk Limited Formulations including 5-[3-(3-hydroxyphenoxy)azetidin-1-yl]-5-methyl-2,2-diphenylhexanamide

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0009606D0 (en) * 2000-04-18 2000-06-07 Glaxo Group Ltd Therapeutic combinations
US6696462B2 (en) * 2002-01-31 2004-02-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Anticholinergics, processes for the preparation thereof, and pharmaceutical compositions
MXPA06004244A (es) * 2003-10-14 2006-06-28 Glaxo Group Ltd Antagonistas del receptor muscarinico de la acetilcolina.

Also Published As

Publication number Publication date
WO2009036243A1 (en) 2009-03-19
JP2010539182A (ja) 2010-12-16
RU2010108640A (ru) 2011-10-20
EP2197444A1 (en) 2010-06-23
US20100329996A1 (en) 2010-12-30
KR20100063116A (ko) 2010-06-10
CN101801378A (zh) 2010-08-11
BRPI0816255A2 (pt) 2015-03-17

Similar Documents

Publication Publication Date Title
MX2010002781A (es) Combinacion novedosa de angentes terapeuticos.
MY184864A (en) Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonist
NZ594140A (en) C5ar antagonists
MX2009006304A (es) Nuevos compuestos de oxadiazol.
TW200635897A (en) Piperidine derivatives and their use as anti-inflammatory agents
WO2007051062A3 (en) Substituted dihydropyridines and methods of use
WO2009050136A3 (en) Glucocorticoid receptor antagonists such as mifepristone for treating cushing' s syndrome
MX2009004662A (es) Compuestos de pirazolina como antagonistas receptores de mineralocorticoides.
TW200726765A (en) Triazolopyridine cannabinoid receptor 1 antagonists
IN2012DN02702A (es)
MY144753A (en) Muscarinic acetylcholine receptor antagonists
MA29662B1 (fr) Compositions pour l'apport de medicaments hautement solubles dans l'eau
MX2007008379A (es) Metodos y composiciones para minimizar la acumulacion de insulina inhlable en los pulmones.
MX2010006204A (es) Derivados de oxindol 5,6-disubstituidos y el uso de los mismos para el tratamiento de enfermedades dependientes de la vasopresina.
PT1729753E (pt) Utilização de um antagonista dos receptores de nmda para o tratamento de zumbido induzido por excitotoxicidade coclear
WO2009082038A3 (en) Ampa receptor antagonists and zonisamide for epilepsy
IL202111A0 (en) Formulations for the oral administration of therapeutic agents and related methods
MX2009008363A (es) Combinacion de un antagonista de receptor muscarinico y un agonista de receptor adrenergico beta 2.
EP2032127A4 (en) TREATMENT OF PSYCHOLOGICAL PATHOLOGIES USING M1 MUSCARINIC RECEPTOR ANTAGONISTS
TW200613302A (en) Nk1 antagonists
TW200633715A (en) Medical combinations
MX2024013184A (es) Metodos y composiciones para tratar apnea del sue?o
TW200633706A (en) Medical combinations
MX2007004976A (es) Antagonistas de receptor m1 y/o m3 en combinacion con otros compuestos activos para tratar trastornos respiratorios.
WO2007094876A3 (en) Methods of transdermally administering an indole serotonin receptor agonist and transdermal compositions for use in the same

Legal Events

Date Code Title Description
FA Abandonment or withdrawal